Effects of Rifampin and Doxycycline Treatments in Patients With Uncomplicated Scrub Typhus: An Open-Label, Randomized, Controlled Trial

被引:15
|
作者
Kim, Yun Sung [1 ]
Kim, Dong-Min [1 ]
Yoon, Na-Ra [1 ]
Jang, Mi-Sun [1 ]
Kim, Choon-Mee [2 ]
机构
[1] Chosun Univ, Coll Med, Dept Internal Med, 588 Seosuk Dong, Gwangju 501717, South Korea
[2] Chosun Univ, Coll Med, Premed Sci, Gwangju, South Korea
关键词
scrub typhus; doxycycline; rifampin; Orientia tsutsugamushi; ORIENTIA-TSUTSUGAMUSHI; NORTHERN THAILAND; CLINICAL-PRACTICE; CHLORAMPHENICOL; AZITHROMYCIN; INFECTIONS; THERAPY; DISEASE;
D O I
10.1093/cid/ciy130
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Doxycycline is currently the most frequently used treatment in patients with scrub typhus. However, doxycycline-resistant strains have been found, necessitating the development of a new treatment. Rifampin is known to be effective even for such strains. Our aim in this study was to compare the effects of rifampin and doxycycline treatment in patients with scrub typhus in areas in which resistance to doxycycline has not been reported. Methods. Patients admitted to Chosun University Hospital and regional network hospitals between 2007 and 2009 with a body temperature >= 37.5 degrees C and suspected to have scrub typhus were randomly assigned to 1 of 2 treatment groups: a group administered doxycycline 100 mg twice daily for 5 days and a group administered rifampin 600 mg once daily for 5 days. For treatment outcomes, fever, headache, muscle ache, and rash clearance times were compared between the groups. Results. The rifampin and doxycycline groups showed equivalence in all treatment outcomes evaluated. The proportions of patients with fever clearance within 48 hours were similar between groups. Furthermore, there was no significant difference in the occurrence of side effects following drug administration between groups. Conclusions. On the basis of the finding that equivalent treatment effects and safety were found in patient groups that received 600 mg of rifampin and 200 mg of doxycycline, respectively, for 5 days to treat scrub typhus, rifampin may be considered an alternative treatment to doxycycline.
引用
收藏
页码:600 / 605
页数:6
相关论文
共 50 条
  • [41] Deceptive and open-label placebo effects in experimentally induced guilt: a randomized controlled trial in healthy subjects
    Sezer, Dilan
    Locher, Cosima
    Gaab, Jens
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [42] Deceptive and open-label placebo effects in experimentally induced guilt: a randomized controlled trial in healthy subjects
    Dilan Sezer
    Cosima Locher
    Jens Gaab
    Scientific Reports, 12
  • [43] Effects of an open-label placebo intervention on reactions to social exclusion in healthy adults: a randomized controlled trial
    Leonie Stumpp
    Melissa Jauch
    Dilan Sezer
    Jens Gaab
    Rainer Greifeneder
    Scientific Reports, 13 (1)
  • [44] Effects of an open-label placebo intervention on reactions to social exclusion in healthy adults: a randomized controlled trial
    Stumpp, Leonie
    Jauch, Melissa
    Sezer, Dilan
    Gaab, Jens
    Greifeneder, Rainer
    SCIENTIFIC REPORTS, 2023, 13 (01):
  • [45] Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: A randomized, open-label controlled trial
    Maity, Nabakumar
    Ghosal, Malay Kumar
    Gupta, Anupam
    Sil, Amrita
    Chakraborty, Sushmita
    Chatterjee, Suparna
    INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 (04) : 433 - 437
  • [46] Tocilizumab in patients with moderate or severe COVID-19:a randomized, controlled, open-label, multicenter trial
    Dongsheng Wang
    Binqing Fu
    Zhen Peng
    Dongliang Yang
    Mingfeng Han
    Min Li
    Yun Yang
    Tianjun Yang
    Liangye Sun
    Wei Li
    Wei Shi
    Xin Yao
    Yan Ma
    Fei Xu
    Xiaojing Wang
    Jun Chen
    Daqing Xia
    Yubei Sun
    Lin Dong
    Jumei Wang
    Xiaoyu Zhu
    Min Zhang
    Yonggang Zhou
    Aijun Pan
    Xiaowen Hu
    Xiaodong Mei
    Haiming Wei
    Xiaoling Xu
    Frontiers of Medicine, 2021, 15 (03) : 486 - 494
  • [47] Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): An open-label randomized controlled trial
    Ma, Xinlei
    Yang, Fan
    Wu, Jinzhi
    Xu, Bei
    Jiang, Mengdi
    Sun, Yiduo
    Sun, Chuanying
    Yu, Ye
    Xu, Danyi
    Xiao, Lanlan
    Ren, Chunyun
    Chen, Chunyan
    Ye, Zi
    Liang, Junyu
    Lin, Jin
    Chen, Weiqian
    PLOS MEDICINE, 2023, 20 (06)
  • [48] Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial
    Zhou, Jian-Guo
    Zhou, Nan-Jing
    Zhang, Qiong
    Feng, Yao-yao
    Zhou, Hang
    TRIALS, 2018, 19
  • [49] Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
    Dongsheng Wang
    Binqing Fu
    Zhen Peng
    Dongliang Yang
    Mingfeng Han
    Min Li
    Yun Yang
    Tianjun Yang
    Liangye Sun
    Wei Li
    Wei Shi
    Xin Yao
    Yan Ma
    Fei Xu
    Xiaojing Wang
    Jun Chen
    Daqing Xia
    Yubei Sun
    Lin Dong
    Jumei Wang
    Xiaoyu Zhu
    Min Zhang
    Yonggang Zhou
    Aijun Pan
    Xiaowen Hu
    Xiaodong Mei
    Haiming Wei
    Xiaoling Xu
    Frontiers of Medicine, 2021, 15 : 486 - 494
  • [50] Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial
    Wang, Dongsheng
    Fu, Binqing
    Peng, Zhen
    Yang, Dongliang
    Han, Mingfeng
    Li, Min
    Yang, Yun
    Yang, Tianjun
    Sun, Liangye
    Li, Wei
    Shi, Wei
    Yao, Xin
    Ma, Yan
    Xu, Fei
    Wang, Xiaojing
    Chen, Jun
    Xia, Daqing
    Sun, Yubei
    Dong, Lin
    Wang, Jumei
    Zhu, Xiaoyu
    Zhang, Min
    Zhou, Yonggang
    Pan, Aijun
    Hu, Xiaowen
    Mei, Xiaodong
    Wei, Haiming
    Xu, Xiaoling
    FRONTIERS OF MEDICINE, 2021, 15 (03) : 486 - 494